Home / Tag Archives: Obesity treatment (page 3)

Tag Archives: Obesity treatment

When GLP-1 Therapy Falls Short: Understanding Non-Response in Clinical Practice

Doctor explaining GLP-1 injection therapy to a patient with diabetes during a clinical consultation

Patients who do not respond to GLP-1 therapy are becoming a growing concern in diabetes care, especially as GLP-1 receptor agonists continue to gain popularity for glycemic control and weight management. While clinical trials often show strong benefits, real-world results can vary. So why do some patients fail to respond …

Read More »

Monitoring Patients on GLP-1 Therapy: Are We Tracking the Right Outcomes?

Doctor reviewing GLP-1 therapy data with glucose monitor, injector pen, and patient consultation in clinic setting

As GLP-1 therapies become a long-term cornerstone in diabetes care, monitoring patients on these treatments is gaining renewed attention. Clinicians once focused mainly on A1C and weight, but is that enough today? Much like checking only the speed of a car without looking at fuel or engine health, relying on …

Read More »

Stopping GLP-1 Therapy: New Data Highlight the Challenge of Weight Regain

GLP-1 injection pen and vial next to a weight scale and measuring tape symbolizing weight regain after therapy

Have you ever wondered why weight seems to come back so quickly after stopping a medication that once worked so well? Weight regain after GLP-1 therapy has become a growing concern as more patients discontinue treatments like semaglutide or liraglutide. While these medications are highly effective for weight loss and …

Read More »

GLP-1 Therapy Before Surgery: New Guidance on Managing Aspiration Risk

GLP-1 injection pen with surgical tools in operating room highlighting perioperative medication management and aspiration risk

As GLP-1 receptor agonists become more common in diabetes and weight management, new concerns are emerging around how GLP-1 medications are managed before surgery. What happens when a medication that slows digestion meets anesthesia? Increasingly, clinicians are asking whether continuing these therapies before surgery could raise aspiration risk. Clear protocols …

Read More »

GLP-1 Therapy and Sleep: Could Metabolic Drugs Improve Sleep Quality?

Woman sleeping peacefully with GLP-1 injection pen on bedside table illustrating improved sleep and metabolic therapy

Researchers are beginning to explore how GLP-1 therapies may influence sleep, recovery, and overall metabolic health. Could a medication designed for blood sugar control also help patients sleep better? As surprising as it sounds, emerging evidence suggests a meaningful connection. This article looks at how GLP-1 receptor agonists may indirectly …

Read More »

GLP-1 Drugs and “Food Noise”: The Brain Science Behind Appetite Control

Medical illustration showing GLP-1 appetite signaling between the gut and brain with reduced food cravings and appetite control

Many patients describe a surprising shift when starting GLP-1 therapies: cravings feel quieter, and the constant pull toward food seems to fade. This experience, often called “food noise,” reflects deeper biological changes driven by GLP-1–based appetite signaling in the body. But what exactly is happening in the brain, and how …

Read More »

GLP-1 Drugs and Blood Pressure: Why These Diabetes Medications Lower More Than Glucose

GLP-1 diabetes medication with blood pressure monitor illustrating cardiovascular and metabolic health benefits

When managing type 2 diabetes, most people focus on blood sugar. However, what if one medication could also improve heart health at the same time? That is exactly what researchers are discovering about how GLP-1 drugs affect blood pressure. These medications, originally designed to control glucose, are now showing consistent …

Read More »

GLP-1s and Muscle Quality: Beyond Lean Mass Preservation

Medical illustration showing skeletal muscle fibers with mitochondria and GLP-1 therapy effects related to muscle quality in type 2 diabetes

Weight loss conversations often focus on a simple question: how much lean mass is preserved? However, emerging research suggests that the story is more complex. GLP-1 receptor agonists are well known for promoting weight loss and improving glycemic control, but scientists are increasingly examining how these medications influence muscle health …

Read More »

GLP-1s and Gastric Motility Over Time: Does the Body Adapt?

Medical illustration showing GLP-1 therapy affecting gastric motility and stomach emptying in diabetes treatment

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have transformed the management of type 2 diabetes and obesity. However, one question clinicians increasingly ask is whether gastric motility adapts during long-term GLP-1 therapy. These medications slow gastric emptying, which contributes to appetite control and postprandial glucose reduction. Yet the human body often …

Read More »

GLP-1s and Health Economics: Are They Cost-Effective in High-Risk Populations?

GLP-1 injectable pens on financial charts with calculator and healthcare cost analysis documents representing cost effectiveness in diabetes care

GLP-1 receptor agonists have transformed type 2 diabetes and obesity management, but the cost-effectiveness of GLP-1 therapies is now at the center of payer and policy debates. With drugs like semaglutide, liraglutide, dulaglutide, and tirzepatide expanding beyond glycemic control into cardiovascular and weight management, a key question remains: do their …

Read More »